Literature DB >> 1127967

Heparin therapy during extracorporeal circulation. II. The use of a dose-response curve to individualize heparin and protamine dosage.

B S Bull, W M Huse, F S Brauer, R A Korpman.   

Abstract

Because the administration of heparin and protamine according to a set protocol will fail to anticoagulate safely or neutralize appropriately a significant number of patients, a method of monitoring heparin therapy during cardiopulmonary bypass is presented. A dose response curve relating heparin dosage to its effect on the activated coagulation time (ACT) can be determined with sufficient accuracy for clinical purposes from three ACT's. Preparation of such a curve makes it possible to maintain anticoagulation in a safe range during bypass and minimizes the number of monitoring tests of coagulation required. At the conclusion of bypass, this curve can be used to predict the precise amount of protamine needed for neutralization. Freed from the confusing effects of hyperheparinemia or protamine excess, the physician can diagnose and treat postoperative bleeding problems much more readily.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1127967

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  53 in total

1.  Safety of low dose heparin in elective coronary angioplasty.

Authors:  K T Koch; J J Piek; R J de Winter; G K David; K Mulder; J G Tijssen; K I Lie
Journal:  Heart       Date:  1997-06       Impact factor: 5.994

2.  All ACTs are not created equal.

Authors:  J J Ferguson
Journal:  Tex Heart Inst J       Date:  1992

3.  An evaluation of two activated clotting time monitors during cardiac surgery.

Authors:  D L Reich; K Zahl; M H Perucho; D M Thys
Journal:  J Clin Monit       Date:  1992-01

Review 4.  The hemostatic defect of cardiopulmonary bypass.

Authors:  Matthew Dean Linden
Journal:  J Thromb Thrombolysis       Date:  2003-12       Impact factor: 2.300

5.  Comparison of point-of-care activated clotting time systems utilized in a single pediatric institution.

Authors:  Jorge W Ojito; Robert L Hannan; Michelle Moore Burgos; Hyunsoo Lim; Monique Huynh; Evelio Velis; Marino Arocha; Christopher F Tirotta; Redmond P Burke
Journal:  J Extra Corpor Technol       Date:  2012-03

6.  [Use of ECMO in adult patients with cardiogenic shock: a position paper of the Austrian Society of Cardiology].

Authors:  Philipp Pichler; Herwig Antretter; Martin Dünser; Stephan Eschertzhuber; Roman Gottardi; Gottfried Heinz; Gerhard Pölzl; Ingrid Pretsch; Angelika Rajek; Andrä Wasler; Daniel Zimpfer; Alexander Geppert
Journal:  Med Klin Intensivmed Notfmed       Date:  2015-09       Impact factor: 0.840

7.  Effective haemostasis during cardiac surgery.

Authors:  J C Horrow; N Ellison
Journal:  Can J Anaesth       Date:  1992-04       Impact factor: 5.063

8.  Sensitivity of a modified ACT test to levels of bivalirudin used during cardiac surgery.

Authors:  Marcia L Zucker; Andreas Koster; Jayne Prats; Frank M Laduca
Journal:  J Extra Corpor Technol       Date:  2005-12

9.  Comparison of routine laboratory measures of heparin anticoagulation for neonates on extracorporeal membrane oxygenation.

Authors:  Jason P Sulkowski; Thomas J Preston; Jennifer N Cooper; Victoria L Duffy; Katherine J Deans; Louis G Chicoine; Peter C Minneci
Journal:  J Extra Corpor Technol       Date:  2014-03

10.  New "multicolor" polypeptide diamagnetic chemical exchange saturation transfer (DIACEST) contrast agents for MRI.

Authors:  Michael T McMahon; Assaf A Gilad; Marco A DeLiso; Stacey M Cromer Berman; Jeff W M Bulte; Peter C M van Zijl
Journal:  Magn Reson Med       Date:  2008-10       Impact factor: 4.668

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.